Comparative effects of bevacizumab, ranibizumab and pegaptanib at intravitreal dose range on endothelial cells
- 31 March 2009
- journal article
- research article
- Published by Elsevier in Experimental Eye Research
- Vol. 88 (3), 522-527
- https://doi.org/10.1016/j.exer.2008.11.011
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Pegaptanib sodium for the treatment of age-related macular degenerationExpert Opinion on Pharmacotherapy, 2008
- Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cellsAngiogenesis, 2007
- TREATMENT OF NAÏVE LESIONS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PEGAPTANIBRetina, 2007
- Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effectsJournal of Cellular Biochemistry, 2007
- Antiangiogenesis to treat cancer and intraocular neovascular disordersLaboratory Investigation, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular DegenerationNew England Journal of Medicine, 2006
- Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal AdministrationInvestigative Opthalmology & Visual Science, 2005
- Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitroAngiogenesis, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004